Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671)....

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Nagamu, Kobayashi, Kiyonori, Naganuma, Makoto, Hirai, Fumihito, Ozawa, Morio, Arikan, Dilek, Huang, Bidan, Robinson, Anne M., Thakkar, Roopal B., Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478765/
https://www.ncbi.nlm.nih.gov/pubmed/28670237
http://dx.doi.org/10.5217/ir.2017.15.3.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478765/
https://www.ncbi.nlm.nih.gov/pubmed/28670237
http://dx.doi.org/10.5217/ir.2017.15.3.395

Ejemplares similares